Wet AMD Pipeline Advances with Over 60 Companies Developing New Treatments
A market research report indicates that over 60 companies are developing more than 75 pipeline drugs for wet age-related macular degeneration (Wet AMD). Several clinical trials are actively underway.
More than 60 companies are actively developing over 75 pipeline drugs for wet age-related macular degeneration (Wet AMD), according to a new report by DelveInsight titled "Wet-AMD Pipeline Insight 2026." The report provides a comprehensive overview of the companies and therapies in various stages of development.
The pipeline includes drugs in both clinical and preclinical stages. Recent developments highlighted include EyePoint Pharmaceuticals initiating a Phase 3 trial for EYP-1901 in July 2026, comparing it against Aflibercept. Genentech and Boehringer Ingelheim have also commenced Phase I/II studies for novel treatments targeting Wet AMD and related conditions such as diabetic macular edema.
Key players identified in the Wet AMD space include Sylentis, Molecular Partners, Sam Chun Dang Pharm, and REGENXBIO, among others. Emerging therapies under investigation feature treatments like RGX-314, CLS-AX, and SYL1801, aiming to improve upon existing treatment paradigms that often require frequent intravitreal injections.
Wet AMD is a severe form of age-related macular degeneration that can rapidly lead to significant vision loss. It is characterized by the growth of abnormal blood vessels under the macula, causing leakage and scarring. The expanding pipeline suggests ongoing efforts to find more effective and potentially longer-lasting treatments.